The synthetic pentasaccharide fondaparinux reduces coagulation, inflammation and neutrophil accumulation in kidney ischemia-reperfusion injury

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 3, 2005, Pages 531-540

  Frank, R D ^a,b   Schabbauer, G ^a   Holscher, T ^a   Sato, Y ^a   Tencati, M ^a   Pawlinski, R ^a   Mackman, Nigel ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FONDAPARINUX; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN; PADGEM PROTEIN; POLYSACCHARIDE; PROTEIN MACROPHAGE INFLAMMATORY PROTEIN 6; UNCLASSIFIED DRUG; CREATINE; FIBRIN; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOKINE;

ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; FIBRIN DEPOSITION; INFLAMMATION; KIDNEY ISCHEMIA; LEUKOCYTE ACTIVATION; MALE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REPERFUSION INJURY; ANIMAL; BLOOD; CELL MOTION; DRUG SCREENING; KIDNEY; METABOLISM; PATHOLOGY; SURVIVAL RATE; VASCULARIZATION;

ANIMALS; BLOOD COAGULATION; CELL MOVEMENT; CREATINE; DRUG EVALUATION, PRECLINICAL; FIBRIN; INFLAMMATION; INTERLEUKIN-6; KIDNEY; MICE; MODELS, ANIMAL; MONOKINES; NEUTROPHILS; POLYSACCHARIDES; REPERFUSION INJURY; SURVIVAL RATE;

EID: 23944497671     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01188.x     Document Type: Article

References (50)

1. Turpie AG, Eriksson BI, Lassen MR, Bauer KA. Fondaparinux, the first selective factor Xa inhibitor. Curr Opin Hematol 2003; 10: 327-32.
2. Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997; 86: 1-36.
3. Beguin S, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost 1989; 61: 397-401.
4. Herault JP, Bernat A, Gaich C, Herbert M. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats. Thromb Haemost 2002; 87: 238-44.
5. Hobbelen PM, van Dinther TG, Vogel GM, van Boeckel CA, Moelker HC, Meuleman DG. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemost 1990; 63: 265-70.
6. Herbert JM, Herault JP, Bernat A, van Amsterdam RG, Lormeau JC, Petitou M, van Boeckel C, Hoffmann P, Meuleman DG. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91: 4197-205.
7. Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 1987; 46: 187-98.
8. Lorrain J, Lechaire I, Gauffeny C, Masson R, Roome N, Herault JP, O'Connor SE, Schaeffer P, Herbert JM. Effects of SanOrgl23781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel. J Pharmacol Exp Ther 2004; 309: 235-40.
9. Bernat A, Hoffmann P, Herbert JM. Antagonism of SR 90107A/Org 31540-induced bleeding by protamine sulfate in rats and mice. Thromb Haemost 1996; 76: 715-19.
10. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1298-304.
11. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-10.
12. Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619-25.
13. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74.
14. Tyrrell DJ, Horne AP, Holme KR, Preuss JM, Page CP. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999; 46: 151-208.
15. Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002; 110: 127-36.
16. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101: 877-89.
17. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993; 82: 3253-8.
18. Erlich JH, Boyle EM Jr, Labriola J, Kovacich JC, Santucci RA, Fearns C, Morgan EN, Yun W, Luther T, Kojikawa O, Martin TR, Pohlman TH, Verrier ED, Mackman N. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemiareperfusion injury by reducing inflammation. Am J Pathol 2000; 157: 1849-62.
19. Okusa MD. The inflammatory cascade in acute ischemic renal failure. Nephron 2002; 90: 133-8.
20. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996; 334: 1448-60.
21. Brezis M, Rosen S. Hypoxia of the renal medulla - its implications for disease. N Engl J Med 1995; 332: 647-55.
22. Shanley PF, Rosen MD, Brezis M, Suva P, Epstein FH, Rosen S. Topography of focal proximal tubular necrosis after ischemia with reflow in the rat kidney. Am J Pathol 1986; 122: 462-8.
23. van Why SK, Kim S, Geibel J, Seebach FA, Kashgarian M, Siegel NJ. Thresholds for cellular disruption and activation of the stress response in renal epithelia. Am J Physiol 1999; 277: F227-F234.
24. Rabb H, O'Meara YM, Maderna P, Coleman P, Brady HR. Leukocytes, cell adhesion molecules and ischemic acute renal failure. Kidney Int 1997; 51: 1463-8.
25. Rabb H, Mendiola CC, Saba SR, Dietz JR, Smith CW, Bonventre JV, Ramirez G. Antibodies to ICAM-1 protect kidneys in severe ischemic reperfusion injury. Biochem Biophys Res Commun 1995; 211: 67-73.
26. Kelly KJ, Williams WW Jr, Colvin RB, Meehan SM, Springer TA, Gutierrez-Ramos JC, Bonventre JV. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 1996; 97: 1056-63.
27. Singbartl K, Green SA, Ley K. Blocking P-selectin protects from ischemia/reperfusion-induced acute renal failure. FASEB J 2000; 14: 48-54.
28. Singbartl K, Ley K. Protection from ischemia-reperfusion induced severe acute renal failure by blocking E-selectin. Crit Care Med 2000; 28: 2507-14.
29. Mizutani A, Okajima K, Uchiba M, Noguchi T. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 2000; 95: 3781-7.
30. Creasey AA, Chang AC, Feigen L, Wun TC, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from E. coli septic shock. J Clin Invest 1993; 91: 2850-6.
31. Taylor FB Jr, Emerson TE Jr, Jordan R, Chang AK, Blick KE. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1998; 26: 227-35.
32. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-25.
33. Mizutani A, Okajima K, Uchiba M, Isobe H, Harada N, Mizutani S, Noguchi T. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003; 101: 3029-36.
34. Ushigome H, Sano H, Okamoto M, Kadotani Y, Nakamura K, Akioka K, Yoshimura R, Ohmori Y, Yoshimura N. The role of tissue factor in renal ischemic reperfusion injury of the rat. J Surg Res 2002; 102: 102-9.
35. Matsuyama M, Yoshimura R, Akioka K, Okamoto M, Ushigome H, Kadotani Y, Nakatani T, Yoshimura N. Tissue factor antisense oligonucleotides prevent renal ischemia-reperfusion injury. Transplantation 2003; 76: 786-91.
36. Matsuyama M, Akioka K, Okamoto M, Kadotani Y, Ushigome H, Nakamura K, Yoshimura R, Ohmori Y, Yoshimura N. The role of tissue factor in renal ischemic reperfusion injury by antisense oligodeoxynucleotide. Transplant Proc 2002; 34: 1475-6.
37. Pawlinski R, Pedersen B, Schabbauer G, Tencati M, Holscher T, Boisvert W, Andrade-Gordon P, Frank RD, Mackman N. Role of tissue factor and protease activated receptors in a mouse model of endotoxemia. Blood 2004; 103: 1342-7.
38. Pawlinski R, Mackman N. Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis. Crit Care Med 2004; 32: S293-S297.
39. Kale S, Karihaloo A, Clark PR, Kashgarian M, Krause DS, Cantley LG. Bone marrow stem cells contribute to the repair of the ischemically injured renal tubule. J Clin Invest 2003; 112: 42-9.
40. Gerotziafas GT, Elalamy I, Depasse F, Chakroun T, Bara L, Arzoglou P, Samama MM. On the mechanism of inhibition of tissue factor pathway by the synthetic pentasaccharide during coagulation of human plasma. Blood Coagul Fibrinolysis 2003; 14: 633-8.
41. Mulligan MS, Paulson JC, De Frees S, Zheng ZL, Lowe JB, Ward PA. Protective effects of oligosaccharides in P-selectin-dependent lung injury. Nature 1993; 364: 149-51.
42. Tedder TF, Steeber DA, Pizcueta P. 1-selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites. J Exp Med 1995; 181: 2259-64.
43. Frenette PS, Mayadas TN, Rayburn H, Hynes RO, Wagner DD. Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins. Cell 1996; 84: 563-74.
44. Lormeau JC, Herault JP. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost 1995; 74: 1474-7.
45. Bachli EB, Pech CM, Johnson KM, Johnson DJ, Tuddenham EG, McVey JH. Factor Xa and thrombin, but not factor VIIa, elicit specific cellular responses in dermal fibroblasts. J Thromb Haemost 2003; 1: 1935-44.
46. Riewald M, Kravchenko V, Petrovan R, O'Brien PJ, Brass LF, Ulevitch RJ, Ruf W. Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1. Blood 2001; 97: 3109-16.
47. Akashi S, Shimazu R, Ogata H, Nagai Y, Takeda K, Kimoto M, Miyake K. Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J lmmunol 2000; 164: 3471-5.
48. Yamaguchi Y, Okabe K, Liang J, Matsumura F, Ohshiro H, Ishihara K, Matsuda T, Takeya M, Kuratsu JI, Mori K, Yamada S, Ogawa M. A synthetic selective inhibitor of factor Xa, DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver. Dig Dis Sci 1999; 44: 2568-76.
49. Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA 2001; 98: 7742-7.
50. Shin CS, Han JU, Kirn JL, Schenarts PJ, Traber LD, Hawkins H, Traber DL. Heparin attenuated neutrophil infiltration but did not affect renal injury induced by ischemia reperfusion. Yonsei Med J 1997; 38: 133-41.